Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...

New genetic risk factors for depression have been identified across all major global populations for the first time, allowing scientists to predict risk of depression regardless of ethnicity.

The narcolepsy treatment market is projected to grow from USD 5,301.6 million in 2024 to USD 8,718.3 million by 2034, at a ...

At the start of each of the last five years, the share price of Alkermes has increased. It’s the kind of steady trajectory ...

Many of us feel drowsy during the day, but what causes it, and what can we do about it when it becomes a problem? Sleep ...

The Assistance Fund, an independent charitable patient assistance organization that helps patients and families facing high medical out-of-pocket costs, today announced the launch of a new copay ...

With the continued execution of our commercial launch in narcolepsy and ongoing progress in our Phase 3 trial in idiopathic ... Our approach includes applying innovative solutions to the development ...

The excessive daytime sleepiness market drowsiness was projected to be worth USD 4.9 billion in 2022. With an expected CAGR of 8.8% from 2023 to 2033, this market is expected to earn USD 5.33 billion ...

Central nervous system (CNS) specialist Neuraxpharm Group has acquired Provigil (modafinil) and Nuvigil (armodafinil), both ...

Even in the winter, you'll want to protect your eyes. These are the best prescription sunglasses to help you do just that. Executive Editor David Carnoy has been a leading member of CNET's Reviews ...

HARTFORD, Conn. — A doctor sued for providing "unnecessary controlled substances" to his patients has agreed to pay an over $455,000 settlement to resolve those allegations. Naimetulla Ahmed ...